IMC Insider Trading (Immuron)
Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): A$0.00
Insider Selling (Last 12 Months): A$0.00
Immuron Share Price & Price History
Current Price: A$0.00
Price Change: +0.30 (1.20%)
As of 05/13/2020 01:00 AM ET
Being A Successful Trader Just Got Easier…
From 10x Trading Champion Chuck Hughes comes the e-book helping thousands to survive the bear market, “Options trading Made Easy”!
Already full of tools and strategies for success, each copy now comes with a daily Trade of the Day, straight from Chuck to you!
Download your copy now!
Immuron Insider Trading History
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
This Options Expert is Giving Everything Away!
Trading champion Chuck Hughes has exposed the strategies of successful traders and handing them over to new traders like you!
His guide “Options Trading Made Easy” now comes with a Trade of the Day from Chuck himself to help you develop a profitable, pro-level trading account!
Get your copy today!
SEC Filings (Institutional Ownership Changes) for Immuron (ASX:IMC)
Immuron Limited, a biopharmaceutical company, researches, develops, and commercializes polyclonal antibodies in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It markets Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and reduce the symptoms of minor gastro-intestinal disorders, as well as for dietary supplement for digestive tract protection; and Protectyn, an immune supplement to maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) that is in Phase III clinical trials to reduce the risk of contracting travelers' diarrhea, as well as acts as an anti-viral activity against SARS-CoV-2; and IMM-529, which is in clinical development stage focuses on treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and ETEC infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is based in Carlton, Australia.
50 Day Range
52 Week Range
Who are the company insiders with the largest holdings of Immuron?